Phase 1 evaluation of BI-907828 monotherapy in 89 heavily pre-treated patients (NCT03449381) demonstrated a maximally tolerated dose of 60 mg dosed orally once every 21 days, and confirmed that partial responses were observed in over a quarter of liposarcoma patients and in several other MDM2-amplified tumors. Here, MDM2 is linked to liposarcoma.